Tekmira Says Expects to Receive Notice by Sept 30 on DoD's Decision Related to Order on TKM-EBOLA Program
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Department of Defense (DoD) has extended the period of a temporary stop-work order with respect to Tekmira's TKM-Ebola program.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.